Top NYC, NY Biotech Companies With Best Stability & Growth (193)

Investor Backing & Capital Strength: Recent Series C (March 2025) from Dassault Systèmes/Medidata and a $50M Series D (April 2026) funded by Boehringer Ingelheim demonstrate continued access to capital aligned with commercialization plans. Long-standing pharma ties with Otsuka and Boehringer, including sizable milestone frameworks, further reinforce capital strength.

Product Line Growth: Two FDA-authorized products (Rejoyn for MDD; CT-132 for migraine) and a Phase 3–positive schizophrenia PDT (CT-155) expand the portfolio from R&D into early commercialization. Acquisitions and new offerings (Better Therapeutics’ AspyreRx IP and the Click SE initiative) broaden therapeutic scope.

Strategic Partnerships: Enduring alliances with Otsuka and Boehringer, plus a strategic integration investment from Dassault Systèmes/Medidata, indicate strong external validation and go-to-market support. Category-shaping moves like Click SE (aligned with FDA PDURS) aim to deepen co-labeling and pharma collaboration opportunities.

Product Line Growth: Evidence indicates non‑COVID brands and newly launched/acquired assets are expanding, with growth led by Eliquis, Vyndaqel/Vyndamax, oncology biosimilars, Nurtec, and Seagen‑originated therapies such as Padcev.

Future-Ready Strategy: Company materials highlight the Seagen acquisition as a multi‑year oncology growth engine alongside recent approvals and advancing vaccine programs, with numerous pivotal starts planned to add future contributors.

Cost & Operational Efficiency: Disclosures describe a multi‑year cost realignment targeting substantial net savings, alongside deleveraging priorities and expected integration synergies to support margin stability during the revenue mix shift.

Market Expansion: Public materials indicate the network has expanded to 6,000+ research sites across 50+ countries and 25+ sponsors, up from 5,500+ sites cited in late 2025. This footprint growth signals broader geographic reach and increasing demand-side participation.

Strategic Partnerships: Announced partnerships such as the September 2025 RealTime eClinical data-integration open access to 50+ large site networks (2,000+ sites) and enrich marketplace data. Additional integrations (e.g., eClinPro in 2026) reinforce distribution and embed the platform more deeply in site workflows.

Innovation-Driven Growth: The company launched AI-enabled pre-screening, AI site selection, and EHR integration in 2025–2026 to improve patient identification and sponsor decision-making. These capabilities can increase conversion and make the platform more attractive to both sites and sponsors.

Strong Revenue Growth: Full‑year 2025 total revenue rose 23% to $255.9M with software up 11%, highlighting broader adoption and upsell including more hosted deployments. ACV reached $201M on a trailing four‑quarter basis and grew 12% in Q1 2026, with 2026 ACV guided to 10–15% growth.

Strategic Partnerships: Progress in collaborations and co‑founded or partnered programs lifted drug‑discovery revenue (Q1 2026 more than doubled, and 2026 guidance is $55–$65M). The company is pursuing partnerships for oncology assets SGR‑1505 and SGR‑3515 and highlighted potential milestone and liquidity events.

Future-Ready Strategy: Management is transitioning software from term licenses to hosted subscriptions and outlined 2026 priorities to scale the “physics+AI” platform and release the Bunsen agentic AI “co‑scientist.” Feedback suggests this shift should aid scalability and retention even as near‑term revenue recognition is choppy.

Strong Revenue Growth: Reported revenue increased sharply in 2025 and continued to rise in Q1 2026, with management raising full‑year 2026 revenue guidance and signaling improved operating leverage.

Diversified Revenue Streams: Both Diagnostics and the higher‑margin Data & Applications businesses showed growth in recent updates, indicating multiple engines driving the top line.

Strategic Partnerships: The company expanded multi‑year collaborations with major pharmaceutical firms and highlighted a sizable pipeline and contract values that support future demand.

Investor Backing & Capital Strength: A $372M Series D in June 2024 led by a16z with Sanofi participation provides substantial capital to expand the pipeline and AI capabilities. Reports characterize this as a material valuation step-up and part of a sizable overall funding base.

Strategic Partnerships: A first-of-its-kind AI collaboration with Sanofi and OpenAI and an out‑licensing deal of gusacitinib to Sanofi (up to €545M) indicate strong external validation and access to enterprise-scale deployment. These alliances reinforce market credibility while opening channels for co-development and monetization.

Product Line Growth: Ongoing in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor and an anti‑CD226 program) and 2026 updates showing rapid Phase 1 initiation suggest a broadening and advancing portfolio. The rebrand and model shift aim to support a faster-moving, diversified pipeline across immunology and related areas.

Product Line Growth: The May 2026 launch of Flatiron Telescope, an AI analytics platform built on multi‑country longitudinal oncology data, signals active expansion of the product portfolio. Additional 2026 Panoramic prostate cancer datasets spanning the US, UK, and Germany reinforce new offerings.

Strategic Partnerships: Abbott’s March 2026 integration of its precision oncology testing directly into OncoEMR indicates deeper, EMR‑embedded collaborations at the point of care. Such integrations suggest widening partner‑driven reach in community oncology workflows.

Market Expansion: Company materials describe a larger technical and geographic footprint in 2026, with datasets and platforms spanning the US, UK, Germany, and Japan. New cross‑country datasets (e.g., Panoramic prostate cancer) indicate scaling of international real‑world data assets.

Strong Market Position & Advantage: Filings and investor materials position the company as the global leader in transfusion medicine/immunohematology, supported by long‑standing platforms and a large reagent installed base. This entrenched footprint drives durable recurring demand across hospital and donor centers.

Diversified Revenue Streams: The combined portfolio spans core‑lab chemistry and immunoassay, molecular, and point‑of‑care, providing revenue across lab and near‑patient settings even if not the overall market leader. Management highlights non‑respiratory recurring revenues within Labs, Immunohematology, and Cardiac as steady contributors.

Cost & Operational Efficiency: Post‑merger integration has delivered cost and portfolio synergies alongside expanding adjusted margins. These actions indicate improving operational leverage despite mixed top‑line trends.

Profitability: Adjusted EPS and operating margins expanded despite muted top-line trends, including a 31.1% adjusted operating margin in the most recent quarter. Cost and productivity actions supported margin improvement even as sales were flat year over year.

Strong Market Position & Advantage: Leadership in niches such as immunoassays and high-quality proteins (R&D Systems), RNA-ISH (RNAscope), and automated protein analysis (ProteinSimple) underpins competitive strength. In-house manufacturing control over most reagents reinforces quality and consistency across core categories.

Future-Ready Strategy: Focus on cell therapy, proteomic instrumentation, spatial biology, and precision diagnostics has expanded as a share of revenue and aligns with high-growth workflows. Acquisitions and strategic stakes (e.g., Lunaphore, Wilson Wolf/ScaleReady) position the portfolio for emerging demand.

Strong Revenue Growth: Recent results show a meaningful step‑up in 2025 revenue with double‑digit year‑over‑year growth and guidance pointing to continued double‑digit expansion into 2026. Feedback suggests performance was slightly ahead of prior guidance and supported by broad‑based demand across regions and customer segments.

Strong Market Position & Advantage: ONT is described as a clear leader in nanopore sequencing and a co‑leader in long‑reads, differentiated by portability, real‑time analysis, ultra‑long reads, and native DNA/RNA methylation detection. Flagship datasets and assemblies reinforce this positioning.

Market Expansion: Updates highlight accelerating adoption beyond academia into clinical, applied industrial and biopharma use cases, alongside growing high‑throughput deployments on PromethION. Feedback suggests growth was evident across major geographies and end‑markets with notable momentum in regulated and applied settings.

Cost & Operational Efficiency: Cost-savings efforts are positioned as a concrete lever to support improved earnings and fund growth priorities, with an enterprise-wide program targeting substantial savings over multiple years. Guidance frames these actions as part of a broader move toward sustained revenue and earnings improvement beginning in 2026.

Resilient & Sustainable Growth: Growth is presented as re-emerging, with management guiding to a return to modest year-over-year revenue expansion in 2026 after a softer 2025. Improving quarterly trends exiting 2025 and a baseline of modest operational growth excluding divestitures support a narrative of stabilization.

Strong Market Position & Advantage: Scale and global reach are repeatedly highlighted as a stabilizing advantage, with broad geographic coverage and a large portfolio supporting access, supply reach, and competitive standing in off-patent medicines. The strategic shift toward complex generics and specialty brands is framed as reinforcing the company’s long-term positioning against pricing pressures.

Strong Revenue Growth: Financial results show rapid, multi‑year top‑line increases with continued quarterly acceleration and raised full‑year guidance.

Strong Market Position & Advantage: Product performance indicates leadership in BTK inhibitors, with BRUKINSA establishing class momentum supported by head‑to‑head data and broad global approvals.

Innovation-Driven Growth: Pipeline breadth, significant R&D investment, and multiple recent regulatory approvals demonstrate an innovation engine fueling new indications and assets.

Market Expansion: The company is described as operating across many U.S. states with a growing clinic footprint and patient coverage, indicating broadening geographic and delivery reach. Public-facing expansion targets and multi-state service capacity reinforce an intent to continue scaling coverage.

Innovation-Driven Growth: Multiple FDA clearances over time for radiology AI tools are cited, including early regulatory wins and subsequent additions in chest imaging, supporting a narrative of continued product and regulatory progress. The combination of FDA-cleared AI with clinical workflows is positioned as a differentiator that can benefit from wider imaging-AI adoption tailwinds.

Strong Market Position & Advantage: A vertically integrated diagnostics-as-a-service approach that bundles equipment, workflows, radiologists, and AI is presented as a clear differentiator versus pure software vendors. This integrated, ambulatory/primary-care focus is repeatedly framed as an area of niche leadership and traction.